Início › Linfoma de Burkitt › Geórgia
Ensaios clínicos de Linfoma de Burkitt em Geórgia
12 estudos para Linfoma de Burkitt estão buscando participantes em locais em Geórgia.
Cidades em Geórgia
Texto oficial do estudo (Inglês)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- e mais 1
RecrutandoFase 2
366 Days – 46 Years · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Augusta University Medical Center, Augusta
RecrutandoFase 3
Idades de 18 a 39 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
RecrutandoEstudo observacional
Idades de 0 a 38 · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
RecrutandoFase 2
Idades de 1 a 30 · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- e mais 1
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Healthcare of Atlanta at Egleston, Atlanta
RecrutandoFase 2
Idades de 7 a 25 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Atlanta
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06137118Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Winship Cancer Institute, Emory University, Atlanta
- Augusta Cancer Center, Augusta
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de nov. de 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Healthcare of Atlanta, Atlanta
RecrutandoFase 2
Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de mai. de 2025 · NCT03509961Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.